NCT07704047 Recombinant acylated glucagon-like peptide 2 analogue(Chongqing Paijin) Short Bowel Syndrome Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook

Move from a broad disease map to a decision-ready trial dossier. This focused report examines NCT07704047—A Clinical Study of FT1 in Patients With Short Bowel Syndrome—using PatSnap Clinical Trials, Drug & Asset, and Company & Deal Intelligence MCP evidence. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.

MCP evidence snapshot: 16 July 2026; publication date: 17 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.

Why NCT07704047 is a hot trial to watch

Short Bowel Syndrome is increasingly segmented by mechanism, biomarker, line of therapy, geography and endpoint architecture. NCT07704047 is notable because it tests Recombinant acylated glucagon-like peptide 2 analogue(Chongqing Paijin) in a Phase 2 design while Treatment-related Adverse Events serves as the main decision variable. The value of this program will depend on whether the protocol converts biological rationale into a clinically interpretable and operationally credible readout.

PatSnap Clinical Trials MCP makes protocol fields machine-readable, while the companion asset and organization servers add mechanism, development-status and sponsor context.

Trial landscape snapshot

Design and endpoint interpretation

The design should be read as an evidence architecture, not just a phase label. Allocation is Randomized, masking is Quadruple, and the intervention model is Crossover Assignment. Enrollment of 8 participants across China shapes statistical precision, execution risk and external validity. A strong readout will need to be interpreted against baseline risk, prior treatment, assessment schedule, missing-data handling and the clinical relevance of the observed effect.

• Primary: Treatment-related Adverse Events — From the first administration to study completion, appropriately 5 months.
• Primary: Changes in fecal wet weight from baseline to the end of treatment — At the end of the second cycle (each cycle is 5 weeks, with a washout period of at least 6 weeks between two cycles)
• Secondary: Changes in urine volume from baseline to the end of treatment — At the end of the second cycle (each cycle is 5 weeks, with a washout period of at least 6 weeks between two cycles)
• Secondary: The Area Under the Curve from dosing to the time of the last measured concentration (AUC0-t) — Up to 8 days, from Day 29 (the last dose administration) to Day 36 (7 days after the last dose) in each treatment cycle (each cycle is 5 weeks)
• Secondary: Maximum plasma concentration (Cmax) — Up to 8 days, from Day 29 (the last dose administration) to Day 36 (7 days after the last dose) in each treatment cycle (each cycle is 5 weeks)

Benchmark readouts in the surrounding field

• Vamorolone for Duchenne Muscular Dystrophy (Phase 2): TTSTAND velocity(12-month): Difference (LS Mean) = 0.004(95.0% CI, -0.025 to 0.032); Difference (LS Mean) = 0.001(95.0% CI, -0.027 to 0.028); TTSTAND velocity(12-month): Difference (LS Mean) = 0.004(95.0% CI, -0.025 to 0.032); Difference (LS Mean) = 0.001(95.0% CI, -0.027 to 0.028)
• Safety and Efficacy of Tamoxifen in Patients with Duchenne muscular dystrophy: open Label Extension of TAMDMD Trial (Phase 3): SAE = 9.0 %
• Impact and Interplay of Corticosteroid Regimen and Exercise Training on DMD Muscle Function (Phase 2): Change in BMI(Mean) = 1.8 kg/m^2 (Standard Deviation, 1.9); Change in BMI(Mean) = 0.67 kg/m^2 (Standard Deviation, 1.4)

These indexed results are contextual benchmarks rather than direct head-to-head evidence. Cross-trial comparisons can be distorted by population, treatment line, endpoint definition, follow-up and analysis set. Their value is to clarify what magnitude and type of evidence the market already recognizes.

Build a living trial monitor: connect to PatSnap MCP Servers and track protocol changes, primary-completion dates and newly indexed results without manually reconciling separate databases.

Asset and sponsor context

Drug & Asset context: Recombinant acylated glucagon-like peptide 2 analogue(Chongqing Paijin)

Company & Deal Intelligence context: Chongqing Paijin Biotechnology Co Ltd. — http://www.pegbiocq.com

The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can decide whether a positive signal becomes a competitive asset.

White space around this program

• Sharper patient selection: prospective biomarker definitions that identify who is most likely to benefit.
• Clinically interpretable endpoints: outcomes that connect activity with function, symptoms, survival or treatment burden.
• Sequencing evidence: comparative data after the most relevant contemporary standard of care.
• Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
• Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.

What to monitor next

Monitor recruitment status, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. The most important inflection point is not always the headline data release; a change in endpoint, population or ownership can alter probability of success months earlier.

Bottom line

NCT07704047 is a focused lens on Short Bowel Syndrome development. Its value will be determined by whether Recombinant acylated glucagon-like peptide 2 analogue(Chongqing Paijin) can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from existing benchmark readouts.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.